Prolonged Drug Delivery System of PEGylated PAMAM Dendrimers with a Anti-HIV Drug by anneer Selvam and K.R.S. Sambasiva Rao, P. Dinesh Kumar, P.Vijayaraj Kumar, T. P
 





Prolonged Drug Delivery System of PEGylated 
PAMAM Dendrimers with a Anti-HIV Drug 
 
P. Dinesh Kumar*1, P.Vijayaraj Kumar2, T. Panneer Selvam3 and   
K.R.S. Sambasiva Rao1 
 
*1Department of Biotechnology, Acharya Nagarjuna University, Guntur-522510, 
Andrapradesh, India 
2School of Pharmacy, UCSI (University College Sadaya International) University, 
JalanMenaraGading 56000 Cheras, Kuala Lumpur, Malaysia 
3Department of Pharmaceutical Chemistry, PES’s Rajaram and TarabaiBandekar College of 
Pharmacy, Faramagudi, Ponda- 403 401, Goa, India 
Corresponding Author Email Id : dineshclbaid@gmail.com, 
 
 
Polyamidoamine (PAMAM) dendrimers is a new non viral drug carrier. However 
their high surface toxicity limits PAMAM dendrimers application in drug delivery. The 
purpose of present work was aimed to developing and exploring PEGylated G4 and G5 
PAMAM dendrimers for anti HIV drug lamivudine. In this study we successfully 
prepared G4 and G5 PAMAM dendrimers with ethylene diamine core and PEGylated 
with MPEG for surface modifications. Further physiochemical and physiological 
parameter such as UV, IR, TEM, DSC, drug entrapment, drug release and hemolytic 
toxicity of both PEGylated and non PEGylated PAMAM dendrimers were determined 
and compared. Here the PEGylation of PAMAM dendrimers reduce the surface toxicity 
and increase the drug loading capacity of PAMAM dendrimers. Moreover PEGylated 
PAMAM dendrimers had released then drug in controlled and prolonged time. Hence the 
PEGylated PAMAM dendrimers were found as suitable drug delivery carrier for anti HIV 
drug lamivudine. 
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Dendrimers are new class of artificial macromolecules which have attracted much 
interest because of their unique structures and properties (Bosman et al 1999; Tomalia et al 
2002; Newkome et al 1999; Hawker et al 1993; Jansen et al 1994.). Their size, structure, and 
surface properties are highly controllable. In addition, their interiors cavities can encapsulate 
small drug molecules (Liu et al 1999; Stiriba et al 2002; Boas et al 2004; Haba et al 2007.). 
Considering these features, dendrimers are highly attractive materials for application in the 
biomedical field for tasks such as drug delivery and diagnosis (Tomalia 2005; Lee et al 2005; 
Medina et al 2009; Wolinsky et al 2008; Tekade et al 2009.). Among the numerous dendrimers 
used for drug delivery, poly amido amine (PAMAM) and poly propylene imine (PPI) 
dendrimers are the two commercially available and most investigated ones. They were 
reported to effectively improve solubility, stability, and deliver efficacy, decrease side-
effects, and tailor pharmacokinetic and pharmacodynamic behaviours of several families of 
drugs, which reveal the promising future of dendrimer-based drug delivery systems. 
Dendrimers biodistribution and toxicity of dendrimers are strongly affected by surface 
functionalities. Moreover, modification of their surfaces with poly(ethylene glycol) (PEG) 




markedly decreases their toxicity and improves their circulation time, which might 
contribute to their accumulation at target sites, associated with angiogenesis through so-
called enhanced permeation and retention effects (Haba et al 2007). In addition, attachment 
of PEG might increase its ability to encapsulate drugs by enhancing hydration around the 
dendrimer periphery (Umeda et al 2010; Kojima et al 2000.). Acquired immunodeficiency 
syndrome (AIDS) is a degenerative infectious disease of the immune system caused by the 
human immunodeficiency virus (HIV) (Broder et al 1984; Price et al 1988.). The HIV infection, 
which targets the monocytes expressing surface CD4 receptors, eventually produces 
profound defects in cell-mediated immunity. Overtime infection leads to severe depletion of 
CD4 T-lymphocytes (T-cells) resulting in opportunistic infection (OIs) like tuberculosis (TB), 
fungal, viral, protozoal and neoplastic diseases and ultimately death (Bowen et al 1985; Tavel 
et al 1999; Simon et al 2006; Grossman et al 2006.). The search for an effective 
chemotherapeutic treatment against HIV infection has led to the development of agents that 
target specific and critical events in the HIV replicative cycle. The best known and the most 
intensively studied active drugs against HIV are reverse transcriptase (RT) inhibitors, viral 
protease inhibitors, entry inhibitors and, more recently, integrase inhibitors(Calogeropoulou 
et al 2003; Piacenti  2006; De Clercq 2007; Klivanov et al 2009; Dau et al 2009; De Clercq 2007). 
Lamivudine (LMV) is an important antiretroviral drug belonging to the category of reverse 
transcriptase inhibitors. Lamivudine has been shown to be somewhat less toxic than other 
nucleoside reverse transcriptase inhibitors (NRTIs) and active against zidovudine-resistant 
HIV isolates (Perry 1997; Soudeyns 1991; Chu 1991; Coates 1992.)29-32. Intracellularly, LMV is 
phosphorylated to its active triphosphate derivative (lamivudine triphosphate), which 
inhibits HIV reverse transcription via viral DNA chain termination. In addition, lamivudine 
triphosphate inhibits both then RNA and DNA dependent DNA polymerase activities of 
reverse transcriptase, and is a weak inhibitor of mammalian α, β, and γ DNA polymerases. 
Several studies in HIV-1 infected patients have shown that treatment failure and adverse 
effects are associated with low and high plasma concentrations of antiretroviral bioactives 
including LMV. Hence administration of LMV directly to the HIV infected cells is highly 
desirable. Decreasing the required drug doses and preventing or minimizing their action on 
non-infected cells would also reduce the harmful side effects (Product Monograph 
GlaxoSmithkline Shire Biochem 2004; Thomas 2004.).  
The present study was aimed at developing and exploring the use of PEGylated newer 
(ethylene diamine) EDA-PAMAM dendrimers for delivery of anti-hiv drug, lamivudine 
(LMV). Here selection of lamivudine in PEGylated (EDA)- PAMAM dendrimers was based 
on its anti HIV activity, short biological half-life and solubility characteristics. PEGylation of 
EDA- PAMAM dendrimers establishes suitability of PEGylated dendrimer as a drug 
delivery system for LMV. It was observed from the hemolytic study that this delivery 
system could be safely administered through i.v. route. We envisaged that current approach 
will improve the management of drug therapy in HIV patients by delivering the drug at a 
controlled rate for a prolonged period of time. 
 
MATERIALS AND METHODS 
Materials 
Ethylene diamine (EDA) and methylmethacrylate (CDH, India), methanol (Rankem, India). 
MPEG2000 (Sigma, Germany), Cellulose dialysis bag (MWCO 12-14 Kda, Himedia, India), 4 
dimethyl amino pyridine (sd-fine chemicals, India), Lamivudine was a benevolent gift from 
Ranbaxy labs Ltd, India. All other chemicals were reagent grade and used without further 
modification. 




Synthesis of PAMAM Dendrimers 
PAMAM dendrimers of 4th and 5th generations (G4 and G5) were prepared through reported 
Michal addition and amidate reaction (Prajapati et al 2009). Briefly in alight resistance 
environment EDA was reacted with methnolic solution of methyl acrylate ( 5% molar 
excess) to form ester terminated dendrimer. Then excess of methnolic solution of EDA (10% 
excess) for 55h in dark. PAMAM dendrimer G4 and G5 were produced by repeated above 
mentioned reaction sequence. Copper sulphate color reaction was carried out to confirm the 
completion of the each step. Further synthesised PAMAM dendrimer were characterized by 
FTIR and H-NMR. 
Synthesis of MPEG 4-Nitrophenyl Carbonate 
M-PEG 4- nitro phenyl carbonate was proposed by reacting M-PEG with nitro phenyl 
carbonate (Kojima et al 2000).  In THF (400ml) M-PEG (0.05mmol) were added to above 
solution in gradual manner for 1h followed by string in room temperature for 48 h. Finally 
the reaction mixture was evaporated to yield M-PEG 4 nitro phenyl carbonate. Further 
recrystallizations of M-PEG 4 nitrophenyl carbonate mixture for chloroform – diethyl ether 
(10:1, total volume 300- 400ml) to produced purified form M-PEG 4 nitro phenyl carbonate.  
Conjugation of MPEG to PAMAM  
Synthesised G4 or G5 PAMAM dendrimers were reacted with M-PEG 4 nitro phenyl 
carbonate to undergo PEGylation (Kojima et al 2000). Briefly in dimethyl sulfoxide (1ml) 
PAMAM dendrimers G3 or G4 (0.5µmol) was dissolved and solution was stirred to react at 
room temperature for 3 to 6 days (based on the generation of PAMAM dendrimers and PEG 
modification ratio). Then resulted reaction mixture was dialyzed against distilled water for 
72h. Lyophilisation of above solution will yield PEG-PAMAM dendrimer. 
Drug Loading in Formulations 
PEGylated (G4 & G5) non PEGylated PAMAM dendrimers (G4 & G5) were dissolved 
separately in methnol and mixed with aqueous solution of lamivudine (100mol). [37] Further 
incubation of above solution was continued with string for 24 h at 25oC. Then removal of 
free drug from the formulation was carried out by dialyzing in cellulose dialysis bag 
(mwco1000da sigma, Germany)against double distilled water for 10 min. 
Spectrophotometrically estimation was done for above solution (λmax 272nm) (uv.1601 
shimadz japan) to determine indirectly amount of drug loaded in the formulation. Further 
lyophilization of formulation was done and used for further characterization.    
Morphology of the Dendrimers 
Transmission electron microscopy (TEM) was performed to investigate particle size and 
provide information on nanoparticle morphology. Prepared and dialyzed lamivudine 
loaded dendrimer formulations were used for Transmission electron microscopic studies. 
The TEM studies were carried out using 3mm Forman (10.5% plastic powder in amyl 
acetate) coated copper grid (300 mesh) at 60 Kv using negative staining by 2% 
phosphotungstic acid (PTA) for whole generation of dendrimers at 150,000X magnification 
on Philips CM-10 TEM and Fei-Philips Morayagni 268D with digital TEM image analysis 
system at 50-60 Kv. 
Differential Scanning Calorimetry 
Thermal stability and crystallinty changes over range of temperature of LMV loaded 
PEGylated PAMAM dendrimer, drug and PEGylated PAMAM dendrimer were studied by 
differential scanning calorimetry.  In aluminium pan known quantity of sample was placed 
and crimped with lid further pan was analyzed in the sample cell for DSC module. (DSC 




Q10 V9.0 Build 275, TA Instruments, USA). Temperature in the DSC module was increased 
by 10°C/min from 35°C equilibrated temperature under a N2 gas purge. Temperature 
stability and phase transition of sample were obtained from peak in the resulting curve.  
Drug Release studies 
Drug release from known amounts of LMV loaded PEGylated G4 and G5 PAMAM 
dendrimers were determined by dialysis method (Vijayaraj Kumar et al 2007). The dialysis 
bags were filled with a known mass of LMV loaded PEGylated dendritic architectures 
(MWCO 1000 Da) and the dialysis bags were placed in 50 ml of PBS (pH 7.4) at 37ºC with 
slow magnetic stirring under sink conditions. Aliquots of 1 ml were withdrawn from the 
external solution and replaced with the same volume of fresh PBS. The drug concentration 
was detected in a spectrophotometer at 272nm λmax. 
Hemolytic Toxicity of Dendrimer–Drug Systems 
Briefly, in HiAnticlot blood collection vials (Himedia Labs, India) RBC suspension (5% 
hematocrit) of the human blood was collected (Vijayaraj Kumar et al 2007). In normal saline 
(4.5ml), LMV encapsulated PEGylated, non PEGylated formulations, drug solution and 
dendrimers solution (0.5ml) was added in incubated for 1h with RBC suspension. The drug 
and dendrimers in separate tubes were taken in such amount that the resultant final 
concentrations of drug and dendrimer were equivalent in all the cases. The PEGylated 
system of dendrimer–drug complex was taken in amount such that the resultant final 
concentrations of drug and dendrimer were equivalent to that in non-PEGylated systems. 
This allowed comparison of the hemolysis data of the drug, dendrimer, LMV loaded 
PAMAM dendrimers and PEGylated dendrimers to assess the effect of PEGylation on 
hemolysis. After centrifugation, supernatants were taken and diluted with an equal volume 
of normal saline and absorbance was measured at 272nm. To obtain 0 and 100% hemolysis, 
RBC suspension was added to 5 ml of 0.9% NaCl solution (normal saline) and 5 ml distilled 
water, respectively. The degree of hemolysis was determined by the following equation: 
Hemolysis (%) = Abs-Abso / Abs100-Abso × 100 
Where Abs, Abs100, and Abso are the absorbance of sample, a solution of 100% hemolysis, 
and a solution of 0% hemolysis; respectively. 
Stability Studies of PEGylated Dendrimer Formulations 
Stability studies were carried out for LMV loaded PEGylated G4 and G5 PAMAM 
dendrimers. Here sample was stored in 40oc for three months. Drug content and drug 
release studies were carried out to analyze the stability of the formulation.  
 
 RESULTS AND DISCUSSION 
Synthesis of PAMAM Dendrimers 
PAMAM dendrimers of G4 and G5 were synthesized employing ethylenediamine (EDA) as 
initiator core and methylacrylate in appropriate molar ratio was confirmed with copper 
sulphate chelation reaction in which half-generations gave a deep blue colour while a full 
generation dendrimers gave a purple color. Further confirmation of synthesized dendrimer 
was carried out by FT-IR, 1H-NMR and microscopic studies. In case of FT-IR spectrum of G4 
PAMAM dendrimer, the presence of peaks at 3438.5 cm-1 (N-H stretching of primary amine); 
1731.1 cm-1 (C=O stretching of ester); 1650.6, 1583.2 cm-1 (-NH-CO stretching of amide); 
1439.9, 1387.8 cm-1 (N-H bending of N substituted); 1208.5, 1030.2 cm-1 (C-O stretching) and 
at 2670 cm-1 (C-H bending peaks) confirmed the synthesis. Similarly in the FT-IR spectrum 




of G5 PAMAM dendrimer, peaks at 3350.2 cm-1 (N-H stretching of primary amine); 3190.0 
cm-1 (N-H stretch anti-symmetric of substituted primary amine); 2890.0 cm-1 (C-H stretch); 
1641.3 cm-1 (C=O stretch of carbonyl group); 1566.0 cm-1, 1327.9 cm-1 (N-H bending of N 
substituted amide); and 1198.5 cm-1 (C-C bending) confirmed the synthesis.  
 
 
Fig. 1. Synthesis of MPEG attached PAMAM dendrimers 
 
Conjugation of MPEG-PAMAM Dendrimers 
The Conjugated synthesis of MPEG-PAMAM dendrimers was confirmed by out by FT-IR, 
1H-NMR and microscopic studies. In IR spectra, the MPEG-PAMAM dendrimers showed 
peaks at 3439 cm-1 for N-H stretching and 1379 cm-1 for N-H bending confirmed the 
Conjugation synthesis of MPEG-PAMAM dendrimers. The recorded IR spectra of 
representative MPEG 4-Nitrophenyl Carbonate showed nitro group band at 1432 cm-1 and 
aromatic band at 3012 cm-1. This peaks are missing in MPEG-PAMAM dendrimers, it’s 
clearly envisages that the nitro group and aromatic ring of MPEG 4-Nitrophenyl Carbonate 
is converted into secondary NH. The proton magnetic resonance spectra of MPEG-PAMAM 
dendrimers and their corresponding derivatives have been recorded in CDCl3. In this NH 
signal of MPEG-PAMAM dendrimers appear at 7.27-7.92 (s) ppm respectively. The position 
and presence of NH signal in the 1H-NMR spectra of final compounds conforms the 
secondary NH proton in MPEG-PAMAM dendrimers. All these observed facts clearly 
demonstrate that the MPEG 4-Nitrophenyl Carbonate is converted into secondary amino 
group as indicated and conforms the proposed structure of MPEG-PAMAM dendrimers. 
Drug Loading 
Since PEGylated PAMAM dendrimer has basic and hydrophobic interior. The entrapment 
efficiency of LMV in PEGylated PAMAM dendrimer is driven by non covalent interaction. 
The entrapment efficacy of LMV in PEGylated PAMAM dendrimer was increased when 
compared with PAMAM dendrimers (Table 1). The significant increase in entrapment of 




LMV in PEGylated PAMAM dendrimers with respect to that of PAMAM dendrimers might 
due to more interaction of drug and mpeg at peripheral portion of dendrimers. 
Table 1. Drug Entrapment and Hemolytic Studies 
Formulation  % Drug 
Entrapped 
% Hemolytic studies 
EDA-PAMAM dendrimer G4 28.21±1.45 15.21±1.56 
EDA-PAMAM dendrimer G5 43.45±1.86 23.21±2.24 
PEG-PAMAM dendrimer G4 54.36±1.23 1.27±0.34 
PEG-PAMAM dendrimer G5 71.54±1.56 1.94±0.56 
 
Morphology of the Dendrimers 
Agglomeration of drug loaded dendrimers lead to form spherical shape dendrimers were 
confirmed by the TEM micrographs (Fig. 2a and 2b). 
Differential Scanning Calorimetry 
DSC curves (Fig 3b) showed that LMV loaded PEGylated PAMAM dendrimers was not a 
physical mixture by endothermic and exothermic transition. DSC graph (Fig 3a) of 
Lamivudine showed their characteristic peak at 1790c. Absence of characteristic peak of 
LMV in the DSC of PEGylated PAMAM G5 dendrimer (Fig 3b) confirmed the drug 
encapsulation in PAMAM dendrimers.   
Drug Release studies 
The drug release profile of LMV from non PEGylated PAMAM dendrimer and PEGylated 
PAMAM dendrimer were shown in Fig 4. The drug release profile showed that release of 
LMV from PEGylated PAMAM dendrimer was significant slower drug release when 
compared with non PEGylated PAMAM dendrimers. While non PEGylated PAMAM 
dendrimers release the drug was 24 h and 36 h respectively and PEGylated PAMAM 
dendrimer release the drug were 96h and 120h. The fact that shows slow release of drug by 
PEGylated PAMAM dendrimers was due hydrophobic interaction between drug and core of 
dendrimer. Moreover difference in the number of terminal peg groups also contributes to 
the slow release of drug.    
 
                




Fig. 2a. Tem image of LMV loaded G5 PEG PAMAM dendrimer, 2b. Tem image of LMV 
loaded G5 PEG PAMAM dendrimer 
 

























































Hemolytic toxicity of non PEGylated amine terminated PAMAM dendrimers showed 15-
25% toxicity. But in PEGylated PAMAM dendrimers haemolysis (toxicity) of RBCs were 
reduced to 2%.  Reduction of haemolysis (toxicity) might be due to surface modification of 
PAMAM dendrimers by PEGylation. In PEGylation inhibition interaction between RBCs 
and quaterny ammonium ion occurs which reduces cytotoxicity nature of PAMAM 
dendrimers.  
Stability 
Three months storage of LMV loaded PEGylated PAMAM dendrimers at 40±20C showed no 
change in appearance and redispersing ability. Moreover there was no significant difference 
in potency and cumulative % drug release (Table 2 and Fig 5). 
 
Table 2. Stability studies of Drug loaded PEG-PAMAM dendrimers 
 
Formulation Appearance % Drug release 
PEG-PAMAM dendrimer G4 Pale yellow color 53.57±2.34 
PEG-PAMAM dendrimer G5 Pale yellow color 70.35±1.54 
CONCLUSION 
In this work we designed PAMAM having PEG grafts as a novel drug carrier. PEG were 
combined to essentially every chain of dendrimers with the generation G4 and G5. 
Moreover we prepared the PEGylated PAMAM dendrimers encapsulating the anti-HIV 
drug lamivudine. While encapsulating ability of PEGylated PAMAM dendrimers are 
increased when compared with non-PEGylated PAMAM dendrimers. Performed drug 
release studies of PEGylated PAMAM dendrimers showed prolong drug release for longer 
time when compared with non-PEGylated PAMAM dendrimers. Hemolytic toxicity studies 
revealed that PEGylated PAMAM dendrimers are relatively low toxicity and safer with non-
PEGylated PAMAM dendrimers. Considering the features of PEGylated PAMAM 
dendrimers, such as highly controlled molecular size, biocompatible surface, encapsulation 
capacity of drug and prolong drug release made them ideal candidate for anti-HIV drug 
therapy. Thus finding obtained in this study provided important information for design 
PAMAM dendrimers as drug carrier for anti-HIV drugs. But further Pharmacokinetic and 
pharmacodynamic aspect of PEGylated PAMAM dendrimer required making them as novel 
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